// App-Quantinova.ai

86 : New insights from the SILVER study; a 50 % reduction in Calcineurin Inhibitors at day 30 does not impact on long‐term renal function after liver transplantation

Researchers

Presenter

  • Bettina M. Buchholz

Principal Investigators

  • James W. Ferguson

  • Andreas Schnitzbauer

  • Peter Nightingale

  • Edward Geissler

  • Darius Mirza

Medical Centers

  • Liver Unit, Queen Elizabeth Hospital Birmingham NHS Trust, Birmingham, United Kingdom

  • Department of General and Visceral Surgery, University Hospital Frankfurt, Frankfurt am Main, Germany

  • Department of Surgery and Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Rapacan

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved